User login
Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, highlights some of the exciting findings on classical Hodgkin lymphoma from the 62nd ASH Annual Meeting and Exposition, held virtually from December 5 to 8, 2020.
The efficacy of brentuximab vedotin (BV) as monotherapy or in combination was evaluated in patients aged 60 and older. Although all regimens appear to be effective, BV plus dacarbazine and BV plus nivolumab were shown to be the most promising combinations.
A 5-year update from the ECHELON-1 trial demonstrated that treatment with BV, doxorubicin, vinblastine, and dacarbazine (A+AVD) maintained reported initial efficacy findings. Many patients with peripheral neuropathy showed improvement or complete resolution at follow up, and most with persisting symptoms had low-grade (grade 1 or 2) neuropathy.
Advanced immune monitoring techniques have revealed details about the T cells in Hodgkin tumors at single-cell resolution. Cytotoxic CD8+ T cells might be antitumor T cells that mediate response to anti-PD1 antibody therapies.
--
Joshua Brody, MD, is the director of the Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine
Dr. Brody has no relevant disclosures.
Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, highlights some of the exciting findings on classical Hodgkin lymphoma from the 62nd ASH Annual Meeting and Exposition, held virtually from December 5 to 8, 2020.
The efficacy of brentuximab vedotin (BV) as monotherapy or in combination was evaluated in patients aged 60 and older. Although all regimens appear to be effective, BV plus dacarbazine and BV plus nivolumab were shown to be the most promising combinations.
A 5-year update from the ECHELON-1 trial demonstrated that treatment with BV, doxorubicin, vinblastine, and dacarbazine (A+AVD) maintained reported initial efficacy findings. Many patients with peripheral neuropathy showed improvement or complete resolution at follow up, and most with persisting symptoms had low-grade (grade 1 or 2) neuropathy.
Advanced immune monitoring techniques have revealed details about the T cells in Hodgkin tumors at single-cell resolution. Cytotoxic CD8+ T cells might be antitumor T cells that mediate response to anti-PD1 antibody therapies.
--
Joshua Brody, MD, is the director of the Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine
Dr. Brody has no relevant disclosures.
Joshua Brody, MD, Director of the Lymphoma Immunotherapy Program at Icahn School of Medicine at Mount Sinai, highlights some of the exciting findings on classical Hodgkin lymphoma from the 62nd ASH Annual Meeting and Exposition, held virtually from December 5 to 8, 2020.
The efficacy of brentuximab vedotin (BV) as monotherapy or in combination was evaluated in patients aged 60 and older. Although all regimens appear to be effective, BV plus dacarbazine and BV plus nivolumab were shown to be the most promising combinations.
A 5-year update from the ECHELON-1 trial demonstrated that treatment with BV, doxorubicin, vinblastine, and dacarbazine (A+AVD) maintained reported initial efficacy findings. Many patients with peripheral neuropathy showed improvement or complete resolution at follow up, and most with persisting symptoms had low-grade (grade 1 or 2) neuropathy.
Advanced immune monitoring techniques have revealed details about the T cells in Hodgkin tumors at single-cell resolution. Cytotoxic CD8+ T cells might be antitumor T cells that mediate response to anti-PD1 antibody therapies.
--
Joshua Brody, MD, is the director of the Lymphoma Immunotherapy Program, Icahn School of Medicine at Mount Sinai, Hess Center for Science and Medicine
Dr. Brody has no relevant disclosures.
